Physician profile
Lawrence C Mann
NPI 1801800990
$11,030.68
in general payments reported to CMS, 2019-2025
55 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,222 · 2020: $901 · 2021: $1,089 · 2022: $3,319 · 2023: $1,467 · 2024: $1,847 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,468 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,467.63 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,569.42 | 2021-2025 | |
| Novo Nordisk INC | $1,153.59 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $829.78 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Amgen INC. | $545.10 | 2019-2025 | Otezla, Repatha, Prolia |
| Merck Sharp & Dohme LLC | $513.51 | 2019-2024 | Verquvo, Gardasil 9, Belsomra |
| Glaxosmithkline, LLC. | $484.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $445.16 | 2019-2022 | |
| Lilly USA, LLC | $416.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $385.19 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $270.01 | 2022 | |
| Astellas Pharma US INC | $251.33 | 2019-2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $250.84 | 2019-2023 | Livalo, Seglentis |
| Sanofi-Aventis U.S. LLC | $209.99 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $203.62 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $186.60 | 2019-2025 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.